Accelagen opens HQ and builds team citing business growth

Australian CRO Accelagen has opened its new headquarters in Melbourne and established a biometric analysis team.

The new HQ, in Melbourne’s Hawthorn East suburb, is a 472 square meter building that will serve as a base for Accelagen’s biometrics business and its clinical trial management, regulatory affairs and consultation units.

In a press statement CEO Greg Plunkett cited drug industry demand for contract research organizations (CROs) offering a range of services as motivation for the investment.

“Expanding the team and adding complementary services in-house, such as our growing Biometrics team, ensures that we can operate as one and enable the development of new therapies that address unmet needs as one team.”

To that end Accelagen has hired 20 additional staff members.

The new HQ comes after a period of growth. While it did not provide any figures, Accelagen said revenues had increased 110% over the past two years.

Customer base

Accelagen also said “client acquisition” has increased 40% over the period, including two COVID-19 vaccine studies from a “renowned international manufacturer.”

Accelagen did not name the manufacturer. However, In October 2020, Cloud software developer SureClinical said it was working with the CRO on a Phase II of a COVID-19 vaccine being developed by the Serum Institute of India.

As well as the expanded customer base, Accelagen said the past two years have been characterized by a high level of repeat business as well as several successful tender bids, including from a “world-leading Swiss-based development company.”

One of the drugs the CRO has worked is RC118, a candidate antibody drug conjugate (ADC) treatment being developed for solid tumors by Remegen and Biocytogen.

Exopharm has also previously named Accelagen as a contractor, explaining in 2019 that the CRO was facilitating a study examining the use of platelet-derived extracellular vesicles as an aid to wound healing.

DepositPhotos/paulo071